<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">HYDROXYUREA</span><br/>(hye-drox'ee-yoo-ree-ah)<br/><span class="topboxtradename">Hydrea, </span><span class="topboxtradename">Droxia<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span>; <span class="classification">antimetabolite</span><br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>The precise mechanism of action is unknown. However, various studies support the hypothesis that hydroxyurea causes an immediate
         inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic
         acid or of protein.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Cytotoxic effect limited to tissues with high rates of cell proliferation. No cross resistance with other antineoplastics
         has been demonstrated.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Palliative treatment of metastatic melanoma, chronic myelocytic leukemia; recurrent metastatic, or inoperable ovarian cancer.
         Also used as adjunct to x-ray therapy for treatment of advanced primary squamous cell (epidermoid) carcinoma of head (excluding
         lip), neck, lungs.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Psoriasis; combination therapy with radiation of lung carcinoma; sickle cell anemia.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Pregnancy (category D), lactation, children, myelosuppression.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Recent use of other cytotoxic drugs or irradiation; renal dysfunction; older adults; history of gout.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Palliative Therapy</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 80 mg/kg q3d or 2030 mg/kg/d<br/><br/><span class="indicationtitle">Sickle Cell Anemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 15 mg/kg/d, may increase by 5 mg/kg/d (max: of 35 mg/kg/d or until toxicity develops)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Open, mix with water, and give immediately when patient has difficulty swallowing capsule.</li>
<li>Store in tightly covered container at 15°30° C (59°86° F) unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Rare: Headache, dizziness, hallucinations, convulsions. <span class="typehead">GI:</span> Stomatitis, anorexia, nausea, vomiting, diarrhea, constipation. <span class="typehead">Hematologic:</span> <span class="speceff-life">Bone marrow suppression</span> (<span class="speceff-common">leukopenia,</span> anemia, thrombocytopenia), megaloblastic erythropoiesis. <span class="typehead">Skin:</span> Maculopapular rash, facial erythema, postirradiation erythema. <span class="typehead">Urogenital:</span> Renal tubular dysfunction, elevated BUN, serum, creatinine levels, hyperuricemia. <span class="typehead">Body as a Whole:</span> Fever, chills, malaise. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 2 h. <span class="typehead">Distribution:</span> Crosses bloodbrain barrier. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Eliminated as respiratory CO<sub>2</sub> and as urea in urine. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Determine status of kidney, liver, and bone marrow function before and periodically during therapy; monitor hemoglobin,
            WBC, platelet counts at least once weekly.
         </li>
<li>Interrupt therapy if WBC drops to 2500/mm<sup>3</sup> or platelets to 100,000/mm<sup>3</sup>.
         </li>
<li>Monitor I&amp;O. Advise patients with high serum uric acid levels to drink at least 1012 240 mL (8 oz) glasses of fluid
            daily to prevent uric acid nephropathy.
         </li>
<li> 							Note: Patients with marked renal dysfunction may rapidly develop visual and auditory hallucinations and hematologic toxicity. 						</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li> 							Note: Incidence of toxicity is as high as 66% with doses of 40 mg/kg body weight. 						</li>
<li>Notify physician of fever, chills, sore throat, nausea, vomiting, diarrhea, loss of appetite, and unusual bruising or bleeding.</li>
<li>Use barrier contraceptive during therapy. Drug is teratogenic.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>